# Phil Young

> Phil Young is a Series A investor at U.S. Venture Partners backing Health Care and Medical. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [U.S. Venture Partners](https://shizune.co/investors/profile/us-venture-partners)
- Location: Menlo Park, United States
- Total investments: 9
- Last investment: Dec 2020
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/phil-young-697a385

Phil Young is a Series A investor at U.S. Venture Partners in Menlo Park focused on Health Care and Medical. Prior to joining US Venture Partners, Phil Young was President & CEO of Oximetrix, a manufacturer of critical care instruments and disposables, where he spent 8 years growing the privately-held venture-backed company from $1 million in revenues to nearly $50 million.Prior to Oximetrix, Phil Young spent 6 years at New Court Securities inventure capital and corporate finance, 2 years as a management consultant with McKinsey & Co., and 6 years on Admiral Rickover's project management staff at the Atomic Energy Commission.Phil Young has represented US Venture Partners on the boards of Aerogen, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, FemRx, Penederm, 3Dfx Interactive, Vical and Xoma--all of which became public companies.Currently Phil Young sits on the boards of Zoran, a public company, as well as Aptus Endosystems, Bayhill Therapeutics, Caspian Networks, Claria, Dotomi, RelayHealth, Synarc, St. Francis Medical and Timi3 Systems.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 56% |
| Medical | 2 | 22% |
| Manufacturing | 2 | 22% |
| Medical Device | 2 | 22% |
| Internet | 1 | 11% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 22% |
| Series B | 2 | 22% |
| Series D | 2 | 22% |
| Series C | 1 | 11% |
| Series E | 1 | 11% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Carlsmed | Provider of medical technology for spine surgery. The company’s proprietary aprevo™ digital-to-device 3-D printed implant system for spine is first-ever surgical implant to be designated by the FDA as a breakthrough technology. Hospital and surgeon customers across the country choose aprevo™ for the benefits of personalized medicine in lumbarfusion surgery.Carlsmed was founded in 2018 and is headquartered in San Diego, California. | $10M | Series A | Dec 16, 2020 |  |
| Aptus Endosystems | Aptus Endosystems is a privately held medical technology company that has developed advanced technology for the endovascular treatment of aortic aneurysm disease. Founded in 2002, Aptus Endosystems has developed a unique endograft and endovascular stapling system that provides a durable alternative to open surgical repair by separating thefunctions of aneurysm exclusion and endograft fixation. The innovative helical staple technology enables independent endograft fixation, and is designed to approximate suturing in an open surgical anastomosis. The result is low profile delivery with no structural compromises, allowing surgeons to treat abdominal aortic aneurysms through a minimally invasive approach while still providing the control of an open surgical repair. The Aptus Endovascular AAA Repair Systems bear the CE Marking for distribution in the European Union. These products are Investigational Use only in the United States.w | $25M | Series B | Jun 27, 2012 |  |
| Aptus Endosystems | Aptus Endosystems is a privately held medical technology company that has developed advanced technology for the endovascular treatment of aortic aneurysm disease. Founded in 2002, Aptus Endosystems has developed a unique endograft and endovascular stapling system that provides a durable alternative to open surgical repair by separating thefunctions of aneurysm exclusion and endograft fixation. The innovative helical staple technology enables independent endograft fixation, and is designed to approximate suturing in an open surgical anastomosis. The result is low profile delivery with no structural compromises, allowing surgeons to treat abdominal aortic aneurysms through a minimally invasive approach while still providing the control of an open surgical repair. The Aptus Endovascular AAA Repair Systems bear the CE Marking for distribution in the European Union. These products are Investigational Use only in the United States.w | $15M | Series A | Aug 30, 2010 |  |
| RelayHealth | RelayHealth provides the connectivity and solutions that enable constituents across healthcare to exchange information securely and conveniently. By connecting patients, providers, pharmacies, payors and pharmaceutical manufacturers, RelayHealth offers real-time solutions to streamline interactions throughout healthcare. The net result: improvedcare, faster access, lower costs and enhanced bottom lines. | $10M | Series F | Jun 01, 2004 |  |
| Synarc | Synarc is the world's largest Central Radiology service dedicated exclusively to clinical trials. Synarc's in-house radiologists and scientists are leading authorities in the use of medical imaging and molecular markers in drug development, and have pioneered many methods currently used in clinical trials. With six offices around theworld, Synarc currently manages over 150 clinical trials, involving more than 50,000 patients at 1,500 sites worldwide. Our services integrate all aspects of the design and execution of imaging and molecular markers in clinical trials across a spectrum of diseases in Oncology, Arthritis, Osteoporosis, Neurology, and Orthopaedics. | $10.2M | Series B | Mar 04, 2004 |  |
| RelayHealth | RelayHealth provides the connectivity and solutions that enable constituents across healthcare to exchange information securely and conveniently. By connecting patients, providers, pharmacies, payors and pharmaceutical manufacturers, RelayHealth offers real-time solutions to streamline interactions throughout healthcare. The net result: improvedcare, faster access, lower costs and enhanced bottom lines. | $6.3M | Series E | Jul 01, 2003 |  |
| Healinx | Healinx is a unique medical relationship management application service provider (ASP). Our mission is to increase communication and the satisfaction level between patients and their doctors, while enhancing physician practice efficiency and profitability.By providing a Web-based channel that links patients directly to their personal doctors,Healinx allows patients to communicate with their doctors or access their medical information anytime -- from anywhere. In addition, patients can receive personalized health information from their doctors. The Healinx customized Internet messaging enables doctors and patients to communicate online with state of the art security and privacy. In addition, the Healinx channel includes a set of tools for electronic prescriptions and preventive care. | $13.1M | Series D | Aug 20, 2001 |  |
| RelayHealth | RelayHealth provides the connectivity and solutions that enable constituents across healthcare to exchange information securely and conveniently. By connecting patients, providers, pharmacies, payors and pharmaceutical manufacturers, RelayHealth offers real-time solutions to streamline interactions throughout healthcare. The net result: improvedcare, faster access, lower costs and enhanced bottom lines. | $13.1M | Series D | Aug 01, 2001 |  |
| Healinx | Healinx is a unique medical relationship management application service provider (ASP). Our mission is to increase communication and the satisfaction level between patients and their doctors, while enhancing physician practice efficiency and profitability.By providing a Web-based channel that links patients directly to their personal doctors,Healinx allows patients to communicate with their doctors or access their medical information anytime -- from anywhere. In addition, patients can receive personalized health information from their doctors. The Healinx customized Internet messaging enables doctors and patients to communicate online with state of the art security and privacy. In addition, the Healinx channel includes a set of tools for electronic prescriptions and preventive care. | $19M | Series C | Feb 23, 2000 |  |

9 of 9 investments shown.

## Co-investors
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 4 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 2 deals together
- [SI Ventures](https://shizune.co/investors/profile/si-ventures) — VC Fund, 2 deals together
- [Concord Ventures](https://shizune.co/investors/profile/concord-ventures) — VC Fund, 1 deal together
- [Cove Fund](https://shizune.co/investors/profile/cove-fund-ii-llc) — VC Fund, 1 deal together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 1 deal together

## About U.S. Venture Partners

VC Fund · Menlo Park, United States

U.S. Venture Partners (USVP) is a venture capital partnership, helping entrepreneurs transform their ideas and efforts into world-changing companies. The firm focuses on early-stage ventures in information technology and health care, where innovation is unbridled and has led to the creation of economic wealth and millions of jobs over the pastthirty-plus years of the firm's existence. Areas of particular interest to our investment professionals include enterprise software, IT security, consumer internet, mobile, and e-commerce, healthcare, and IT-enabled healthcare services. The USVP team consists of former entrepreneurs, technologists, corporate executives, financial professionals, and industry domain experts.

5 contacts available at U.S. Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Phil Young | Senior Advisor | https://shizune.co/investors/profile/phil-young |
| Casey Tansey | General Partner | https://shizune.co/investors/profile/casey-tansey |
| Dafina Toncheva | General Partner | https://shizune.co/investors/profile/dafina-toncheva |
| Dale Holladay | CPA/CFO | https://shizune.co/investors/profile/dale-holladay |
| Jacques Benkoski | General Partner | https://shizune.co/investors/profile/jacques-benkoski |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Phil Young invest in?

Phil Young invests primarily in Health Care, Medical and Manufacturing startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Phil Young last invest?

The most recent investment recorded for Phil Young closed in Dec 2020. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co